Loading patent…
AssigneeNational University Corporation Hokkaido University
InventorsKen Kadoya, Yuki Suzuki, Akihito Sotome, Katsumi Maenaka, Satoko Otsuguro
Estimating the term…
The present invention pertains to a vascular endothelial cell protecting agent, a blood-cerebrospinal fluid barrier protecting agent, and a central nervous system protecting agent, comprising at least one compound selected from the group consisting of mubritinib, brexpiprazole, papaverine, bismuth-containing compounds, and pharmaceutically acceptable salts thereof. Additionally, the present invention pertains to a pharmaceutical composition for preventing and/or treating diseases associated with blood-cerebrospinal fluid barrier impairments, such as damage to the central nervous system, infarction and hemorrhaging, inflammatory diseases of the central nervous system, degenerative diseases of the central nervous system, symptomatic nerve diseases, spinal cord impairments associated with spinal cord degeneration, drug-based impairments, infectious diseases, or anaphylaxis. The pharmaceutical composition comprises at least one compound selected from the group consisting of mubritinib, brexpiprazole, papaverine, bismuth-containing compounds, and pharmaceutically acceptable salts thereof.
A method for protecting the blood brain spinal cord barrier, comprising administering to a subject in need thereof an effective amount of at least one compound selected from the group consisting of a bismuth-containing compound and a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.